Healius share price on watch after trading update

The Healius Ltd (ASX: HLS) share price is on watch as the Aussie healthcare company provided a trading update at its AGM today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Healius Ltd (ASX: HLS) share price is on watch this morning after a trading update provided at the company's annual general meeting (AGM).

a woman

What could move the Healius share price?

While shareholders are waiting to hear from management at the AGM, all eyes will be on the company's trading and management update released this morning.

Healius announced underlying net profit after tax (NPAT) for FY20 is expected to be between $94 million and $102 million, which could see the Healius share price move today.

At the top end of that range, this would represent a 9.4% increase on the prior corresponding period (pcp) as anticipated in the company's 16 August update. Healius would then have delivered in line with the seasonally adjusted run rate from 2H 2019.

The Aussie healthcare company also confirmed a raft of management changes in today's announcement. Scott Beattie will be taking over as CEO of the group's Medical Centres business. These changes all form part of Healius' organisational re-design, which was announced earlier this year.

What else did Healius announce?

Chairman Rob Hubbard noted FY19 was a big year for the Aussie healthcare group. The company rebranded as Healius during the year and rejected a takeover bid from its major shareholder, Jangho, due to share price and conditionality.

In terms of financials, Healius delivered revenue up 6% on pcp to $1.8 billion with underlying NPAT up 6.5% to $93 million as the Healius share price climbed higher in 2019.

Pathology was the company's largest division, with about 60% of the group's profit on the back of a 2H 2019 turnaround. Healius' Medical Centres division grew revenue and EBIT by 13% and 19%, respectively, and the Imaging division delivered a third successive year of double-digit growth.

Mr. Hubbard said FY20 will be the peak year of adjustments to the company's reported earnings. 

Capital expenditure remained higher in FY19, mostly due to strategic investments such as its Montserrat Day Hospitals acquisition.

The Healius share price is up 27.87% to $3.12 per share, prior to this morning's open.

Motley Fool contributor Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »

A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks
Broker Notes

3 reasons to buy Pro Medicus shares today

Two leading investment analysts believe Pro Medicus shares are primed for a rebound.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Healthcare Shares

Should I invest $10,000 into CSL shares? Yes or no

Is it time to pick up this fallen giant? Let's dig deeper into things.

Read more »

A woman scratches her head, thinking is this a no-brainer?
Healthcare Shares

Does this ASX 200 stock's fall make it a no-brainer buy?

Despite a major transformation, this stock is down more than 20%. Is this an opportunity?

Read more »